The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children

BACKGROUND: Drug development for rare diseases is challenging, especially when these orphan drugs (OD) are intended for children. In 2007 the EU Paediatric Drug Regulation was enacted to improve the development of high quality and ethically researched medicines for children through the establishment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreeftmeijer-Vegter, Annemarie Rosan, de Boer, Anthonius, van der Vlugt-Meijer, Roselinda H, de Vries, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237943/
https://www.ncbi.nlm.nih.gov/pubmed/25091201
http://dx.doi.org/10.1186/s13023-014-0120-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237943/
https://www.ncbi.nlm.nih.gov/pubmed/25091201
http://dx.doi.org/10.1186/s13023-014-0120-x

Ejemplares similares